Nomura has maintained its buy rating on CG Power but has cut the target price to Rs 825 from Rs 900 earlier. Analysts said that while the company beat analysts’ estimates on inflows, its railway business dragged down its margin. They feel demand tailwinds are intact for power systems. However, the company is gaining market share in value-added industrial system products.
Citigroup maintained its sell rating on PNB with the target price at Rs 91. Analysts said the lender breached the 1% return on assets rate while its quarterly profit was aided by treasury gains, recoveries. They also pointed out that PNB’s net interest slipped during the quarter and slippages were higher. For FY26 credit growth guidance is at 11-12% and deposits at 9-10%.
Citi maintained its buy rating on HPCL with the target price raised to Rs 510 from Rs 460. Analysts raised FY26/27 EBITDA estimates for HPCL by 10%/5%. The company has changed its marketing and refining margin estimates. Analysts said that the upside to target price could come from a potential LPG compensation from the govt.
Motilal Oswal Financial Services has upgraded Aurobindo Pharma to buy with the target price at Rs 1,360. Analysts feel the company’s showcases diversification and differentiation backed by capacity. It is actively investing across multiple high-potential segments to drive sustained growth over the next 3-5 years. The company stands out for having the most diversified US generic portfolio, demonstrating resilience against pricing pressure. Additionally, it’s investments in differentiated capabilities and facilities for regulated markets position the company well for continued momentum.
Elara Securities India has updated Larsen & Toubro to accumulate rating with the target price at Rs 4,051. Analysts feel L&T’s international projects continue to be its key driver. Its core businesses continue to strengthen and ongoing investment in new-age businesses, such as semiconductors and data centres, may add newer avenues for growth.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
Citigroup maintained its sell rating on PNB with the target price at Rs 91. Analysts said the lender breached the 1% return on assets rate while its quarterly profit was aided by treasury gains, recoveries. They also pointed out that PNB’s net interest slipped during the quarter and slippages were higher. For FY26 credit growth guidance is at 11-12% and deposits at 9-10%.
Citi maintained its buy rating on HPCL with the target price raised to Rs 510 from Rs 460. Analysts raised FY26/27 EBITDA estimates for HPCL by 10%/5%. The company has changed its marketing and refining margin estimates. Analysts said that the upside to target price could come from a potential LPG compensation from the govt.
Motilal Oswal Financial Services has upgraded Aurobindo Pharma to buy with the target price at Rs 1,360. Analysts feel the company’s showcases diversification and differentiation backed by capacity. It is actively investing across multiple high-potential segments to drive sustained growth over the next 3-5 years. The company stands out for having the most diversified US generic portfolio, demonstrating resilience against pricing pressure. Additionally, it’s investments in differentiated capabilities and facilities for regulated markets position the company well for continued momentum.
Elara Securities India has updated Larsen & Toubro to accumulate rating with the target price at Rs 4,051. Analysts feel L&T’s international projects continue to be its key driver. Its core businesses continue to strengthen and ongoing investment in new-age businesses, such as semiconductors and data centres, may add newer avenues for growth.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
You may also like
UN to host first high-level meeting on North Korea's human rights violations
Built a Rs 5,000 cr empire. But Dr A Velumani 'runs away fast' from these kind of people
Operation Sindoor: Know what India has achieved
Doctor practices while suspended, Punjab Medical Council complains to cops but revokes suspension
2nd death in a month: Tiger kills forest ranger in Ranthambore
